Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12.

Neurosurgical focus

Volumn 9, Issue 6, 2000, Pages

  Yamanaka, R ^a   Zullo, S A ^a   Tanaka, R ^a   Ramsey, J ^a   Blaese, M ^a   Xanthopoulos, K G ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; RECOMBINANT PROTEIN;

ANIMAL; APOPTOSIS; ARTICLE; BRAIN TUMOR; C57BL MOUSE; CD8+ T LYMPHOCYTE; CYTOLOGY; DENDRITIC CELL; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSFECTION; GENETICS; GLIOMA; HAMSTER; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY; METHODOLOGY; MOUSE; PATHOLOGY; SEMLIKI FOREST ALPHAVIRUS; SURVIVAL RATE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CRICETINAE; DENDRITIC CELLS; GENE THERAPY; GENETIC ENGINEERING; GLIOMA; IMMUNOTHERAPY; INTERLEUKIN-12; KIDNEY; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SEMLIKI FOREST VIRUS; SURVIVAL RATE; TRANSFECTION;

MLCS; MLOWN;

EID: 0005258572     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/foc.2000.9.6.8     Document Type: Article

References (0)